替米沙坦对下肢外周动脉疾病患者步行能力的影响:TELEX随机临床试验
TELEX随机临床试验在2个美国中心纳入114例下肢外周动脉疾病(PAD)患者,采用2×2析因设计比较替米沙坦与安慰剂对6个月时6分钟步行距离的影响。结果显示替米沙坦组6分钟步行距离变化1.32米,安慰剂组变化12.5米,校正后组间差异为-16.8米(95%CI,-35.9米至2.2米;P=0.08),未显著改善步行能力。
要点
- 替米沙坦与安慰剂相比未显著改善6分钟步行距离,校正组间差异-16.8米(95%CI,-35.9米至2.2米;P=0.08)。
- 替米沙坦与安慰剂相比未显著改善任何5项次要结局。
- 替米沙坦组3例(5.1%)、安慰剂组2例(3.6%)因PAD住院(下肢血运重建、截肢或坏疽)。
核心结论
- 在下肢PAD患者中,替米沙坦与安慰剂相比未改善6个月时的6分钟步行距离,结果不支持替米沙坦用于改善PAD患者的步行能力。
研究设计与样本
- 双盲随机临床试验,在美国2个中心进行,采用2×2析因设计,纳入114例下肢PAD患者。
- 入组时间为2015年12月28日至2021年11月9日,末次随访于2022年5月6日完成。
- 患者随机分为4组:替米沙坦联合运动组(n=30)、替米沙坦联合注意力对照组(n=29)、安慰剂联合运动组(n=28)、安慰剂联合注意力对照组(n=27),干预6个月。
- 原计划样本量为240例;因入组慢于预期,主要比较改为替米沙坦两组合并 vs 安慰剂两组合并,目标样本量改为112例。
- 主要结局为6个月时6分钟步行距离变化(最小临床重要差异8-20米);次要结局为最大跑台步行距离、步行障碍问卷的距离/速度/爬楼梯评分及36项简短健康调查躯体功能评分。
主要发现
- 114例随机患者平均年龄67.3岁(SD,9.9),女性46例(40.4%),黑人81例(71.1%);105例(92%)完成6个月随访。
- 替米沙坦组6分钟步行距离从均值341.6米变为343.0米(组内变化1.32米),安慰剂组从352.3米变为364.8米(组内变化12.5米),校正后组间差异为-16.8米(95%CI,-35.9米至2.2米;P=0.08)。
- 与安慰剂相比,替米沙坦未显著改善任何5项次要结局。
- 最常见的严重不良事件为因PAD住院(即下肢血运重建、截肢或坏疽);替米沙坦组3例(5.1%)、安慰剂组2例(3.6%)因PAD住院。
关键数值与推荐
- 主要结局的校正后组间差异为-16.8米(95%CI,-35.9米至2.2米;P=0.08),未达统计学显著。
- 替米沙坦组6分钟步行距离组内变化1.32米,安慰剂组组内变化12.5米。
- 替米沙坦组因PAD住院3例(5.1%),安慰剂组2例(3.6%)。
临床怎么用
- 原文结论认为结果不支持替米沙坦用于改善PAD患者的步行能力。
局限性
- 因入组慢于预期,原计划样本量240例改为目标样本量112例,主要比较改为替米沙坦两组合并 vs 安慰剂两组合并。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Patients with lower extremity peripheral artery disease (PAD) have reduced lower extremity perfusion, impaired lower extremity skeletal muscle function, and poor walking performance. Telmisartan (an angiotensin receptor blocker) has properties that reverse these abnormalities. OBJECTIVE: To determine whether telmisartan improves 6-minute walk distance, compared with placebo, in patients with lower extremity PAD at 6-month follow-up. DESIGN, SETTING, AND PARTICIPANTS: Double-blind, randomized clinical trial conducted at 2 US sites and involving 114 participants. Enrollment occurred between December 28, 2015, and November 9, 2021. Final follow-up occurred on May 6, 2022. INTERVENTIONS: The trial randomized patients using a 2 × 2 factorial design to compare the effects of telmisartan plus supervised exercise vs telmisartan alone and supervised exercise alone and to compare telmisartan alone vs placebo. Participants with PAD were randomized to 1 of 4 groups: telmisartan plus exercise (n = 30), telmisartan plus attention control (n = 29), placebo plus exercise (n = 28), or placebo plus attention control (n = 27) for 6 months. The originally planned sample size was 240 participants. Due to slower than anticipated enrollment, the primary comparison was changed to the 2 combined telmisartan groups vs the 2 combined placebo groups and the target sample size was changed to 112 participants. MAIN OUTCOMES AND MEASURES: The primary outcome was the 6-month change in 6-minute walk distance (minimum clinically important difference, 8-20 m). The secondary outcomes were maximal treadmill walking distance; Walking Impairment Questionnaire scores for distance, speed, and stair climbing; and the 36-Item Short-Form Health Survey physical functioning score. The results were adjusted for study site, baseline 6-minute walk distance, randomization to exercise vs attention control, sex, and history of heart failure at baseline. RESULTS: Of the 114 randomized patients (mean age, 67.3 [SD, 9.9] years; 46 were women [40.4%]; and 81 were Black individuals [71.1%]), 105 (92%) completed 6-month follow-up. At 6-month follow-up, telmisartan did not significantly improve 6-minute walk distance (from a mean of 341.6 m to 343.0 m; within-group change: 1.32 m) compared with placebo (from a mean of 352.3 m to 364.8 m; within-group change: 12.5 m) and the adjusted between-group difference was -16.8 m (95% CI, -35.9 m to 2.2 m; P = .08). Compared with placebo, telmisartan did not significantly improve any of the 5 secondary outcomes. The most common serious adverse event was hospitalization for PAD (ie, lower extremity revascularization, amputation, or gangrene). Three participants (5.1%) in the telmisartan group and 2 participants (3.6%) in the placebo group were hospitalized for PAD. CONCLUSIONS AND RELEVANCE: Among patients with PAD, telmisartan did not improve 6-minute walk distance at 6-month follow-up compared with placebo. These results do not support telmisartan for improving walking performance in patients with PAD. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT02593110.
引用
- McDermott MM, Bazzano L, Peterson CA, et al. Effect of Telmisartan on Walking Performance in Patients With Lower Extremity Peripheral Artery Disease: The TELEX Randomized Clinical Trial. JAMA. 2022. PMID: 36194220. doi:10.1001/jama.2022.16797
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。